190 related articles for article (PubMed ID: 35068399)
61. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
62. Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Jeong EH; Lee TG; Ko YJ; Kim SY; Kim HR; Kim H; Kim CH
Cell Oncol (Dordr); 2018 Dec; 41(6):663-675. PubMed ID: 30178167
[TBL] [Abstract][Full Text] [Related]
63. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
64. Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer--a review.
Sarita Rajender P; Ramasree D; Bhargavi K; Vasavi M; Uma V
J Recept Signal Transduct Res; 2010 Aug; 30(4):206-13. PubMed ID: 20560705
[TBL] [Abstract][Full Text] [Related]
65. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
Siemeister G; Lücking U; Wengner AM; Lienau P; Steinke W; Schatz C; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2012 Oct; 11(10):2265-73. PubMed ID: 22821149
[TBL] [Abstract][Full Text] [Related]
66. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
67. Animal Models for Studying the In Vivo Functions of Cell Cycle CDKs.
Risal S; Adhikari D; Liu K
Methods Mol Biol; 2016; 1336():155-66. PubMed ID: 26231715
[TBL] [Abstract][Full Text] [Related]
68. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis.
Al-Aynati MM; Radulovich N; Ho J; Tsao MS
Clin Cancer Res; 2004 Oct; 10(19):6598-605. PubMed ID: 15475449
[TBL] [Abstract][Full Text] [Related]
69. Cell cycle, CDKs and cancer: a changing paradigm.
Malumbres M; Barbacid M
Nat Rev Cancer; 2009 Mar; 9(3):153-66. PubMed ID: 19238148
[TBL] [Abstract][Full Text] [Related]
70. Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.
Chen R; Hassankhani R; Long Y; Basnet SKC; Teo T; Yang Y; Mekonnen L; Yu M; Wang S
ChemMedChem; 2023 Feb; 18(3):e202200582. PubMed ID: 36400715
[TBL] [Abstract][Full Text] [Related]
71. Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.
Zhang J; Su G; Lin Y; Meng W; Lai JKL; Qiao L; Li X; Xie X
Discov Med; 2019 Jan; 27(146):27-36. PubMed ID: 30721649
[TBL] [Abstract][Full Text] [Related]
72. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
73. Complexities in the development of cyclin-dependent kinase inhibitor drugs.
Sausville EA
Trends Mol Med; 2002; 8(4 Suppl):S32-7. PubMed ID: 11927285
[TBL] [Abstract][Full Text] [Related]
74. Phenotypic Characterization of Targeted Knockdown of Cyclin-Dependent Kinases in the Intestinal Epithelial Cells.
Lu S; Sung T; Amaro M; Hirakawa B; Jessen B; Hu W
Toxicol Sci; 2020 Sep; 177(1):226-234. PubMed ID: 32556214
[TBL] [Abstract][Full Text] [Related]
75. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction.
Tong J; Tan X; Hao S; Ermine K; Lu X; Liu Z; Jha A; Yu J; Zhang L
Oncogene; 2023 Mar; 42(12):869-880. PubMed ID: 36721000
[TBL] [Abstract][Full Text] [Related]
77. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
78. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
79. Pharmacological relevance of CDK inhibitors in Alzheimer's disease.
Malhotra N; Gupta R; Kumar P
Neurochem Int; 2021 Sep; 148():105115. PubMed ID: 34182065
[TBL] [Abstract][Full Text] [Related]
80. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
